Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Melanoma 2Glioblastoma 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostate Adenocarcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1Brain Diseases 1Adenocarcinoma 1

Interventions

pembrolizumab 51Nivolumab 27Gemcitabine 23atezolizumab 19Cisplatin 18Carboplatin 18enfortumab vedotin 15avelumab 15Mitomycin 14Docetaxel 8Ipilimumab 7Paclitaxel 6Injections 5Cyclophosphamide 5vinflunine 4toripalimab 4tislelizumab 4lenvatinib 4fludarabine 4epacadostat 4Pemetrexed 4130-nm albumin-bound paclitaxel 4sacituzumab govitecan 3disitamab vedotin 3Rogaratinib 3Interleukin-2 3ALT-803 3vofatamab 2valrubicin 2rucaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Transitional Cell × Radiosurgery × Clear all
NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡